Stem Cell Therapy for Autoimmune Disease
Understanding Autoimmune Diseases
Autoimmune disease is a condition in which the immune system of the patient generates cellular and antibody responses to body tissues and substances. The disorder may present itself in one organ or involve a particular tissue in different body organs. Some of the most common autoimmune disorders are lupus, arthritis, and multiple sclerosis. Patients with autoimmune disease have unusual antibodies in their blood system that targets body tissues. As a result, as noted by the International Journal of stem cells, over sixty types of autoimmune diseases affect 6% of the population and are the third-largest disease burden after heart diseases and cancer.
Traditional Ways to Treat Autoimmune Diseases vs Stem Cell Therapy
Conventionally, autoimmune disorders are treated using immune suppressive agents such as steroids, gold, infliximab, cyclosporine and methotrexate which have been found to induce temporary improvements. The medications also pose adverse side effects on the patients; needless to say, the life-long treatment is a significant financial burden.
StemFinity Cord presents a new, plausible, cost-effective and efficient form of treatment – we use stem cell therapy to treat autoimmune disorders.
Stem cell therapy has been proven to induce profound healing activity. It heals damaged tissues as they can modulate the immune system so as prevent pathological responses while preserving their ability to fight off diseases. The most commonly used and the most effective stem cells are allogeneic mesenchymal stem cells extracted from umbilical cord Wharton Jelly. They produce anti-inflammatory agents that help in reducing inflammation produced by autoimmune diseases. The mediators are immune-privileged and also does not suppress the patient’s immune response. Mesenchymal stem cells also lead to the production of T regulatory cells; an immune cell charged with protecting the body against a self-immunological attack.
How Mesenchymal Stem Cells Work
Stem cells are administered through intravenous, intraarterial or intracerebral routes. We have determined that intravenous administration is the most convenient form of delivery of the stem cells and the therapeutic effects of the injury. Intravenously administered mesenchymal stem cells are transiently trapped in the lungs, sequestered in the spleen and predominantly eliminated by the kidneys. The initial accumulation of the stem cells in the lungs induces the production of secondary anti-inflammatory effectors. Clinical benefits of mesenchymal stem cells do not require sustained engraftment of a large number of cells. The therapeutic benefit is obtained by the growth factor’s local production and the provision of temporary paracrine anti-proliferative and immunomodulatory properties. The in vitro culture of mesenchymal stem cells leads to their expansion to more than 1 billion-fold.
Mesenchymal stem cells secrete cytokines that are important for hematopoiesis and can maintain and expand a lineage-specific colony. These form CD34+ cell units from marrow cells in the long bone marrow culture. In vitro, mesenchymal stem cells exhibit immunosuppressive properties; the suppression is a major histocompatibility complex that is independent in human cell cultures.
Research Studies on the Efficacy of Stem Cell Treatment for Autoimmune Diseases
In a study conducted by Ra et al (2011), the report of the outcome of the treatment using culture-expanded human adipose-derived mesenchymal stem cells among 10 patients, the results showed a higher expansion efficiency. The study showed that the high expansion efficiency was routinely derived from autoimmune patients and elderly donors without measurable viability, genetic stability and safety profile loss. Ra et al (2011) also note that in as much the differentiation properties of mesenchymal stem cells are dependent on microenvironmental clues in vivo, the immunomodulatory effects appear to be rather intrinsic. This presents an attractive therapeutic basis for autoimmune and inflammatory diseases by systemic infusion.
In a study detailed by the World Journal of Stem Cells, after 4 years of follow up Systemic lupus erythematosus (SLE) patients who underwent allogeneic bone marrow transplantation, almost 50% of participants experienced clinical remission with an overall survival rate of 94%. The World Journal of Stem Cells as highlights two studies carried out to treat severe refractory rheumatoid arthritis, a type of autoimmune disorder using intravenously administered bone-marrow-derived mesenchymal stem cells. The results showed that the procedure is safe since there were no recorded side effects and significant clinical remission was observed. After six months of the stem cell administration, the level of inflammatory cytokines in the peripheral blood was found to be reduced with an increase in the number of Treg cells.
Approval of Stem Cell Treatments for Autoimmune Diseases
The World Journal of Stem Cells asserts that the progress in clinical trials for the modification of the disease and immunomodulatory or regenerative purposes are encouraging, however, they need further studies on the therapeutic efficacy, potential side effects. The British Society for Rheumatology notes that mesenchymal stem cells are capable of inducing anti-proliferative, anti-inflammatory and immunomodulatory effects inactivated target cells in studied models with autoimmune disorders. These properties coupled with their immunological privilege and low toxicity offer a new strategy for controlling and protecting vital body organs from inflammatory and destructive autoimmune reactions. Substantially, the uniform regulation of the clinical application of stem cells one indispensable characteristic of mesenchymal stem cells.
StemFinity Cord banks on the ability to highly customize the stem cells. The therapeutic procedure is also minimally invasive, and has shown efficacy and proved to be worth accrediting.
In the past decades, we have seen the introduction of many agents that have been tried tested and data obtained from them that have proven vital in developing several therapeutic procedures for autoimmune disorders. Stem cell therapy is one medical procedure that has been studied for decades. StemFinityCord is one such organization that has championed the study of stem cells in the treatment of autoimmune disorders. Our specialists have accumulated years of 24-7 hours of laboratory research work to develop the best methods of treating autoimmune disorders using specifically mesenchymal stem cells.
Autoimmune disorders are not meant to paralyze your life, contacting StemFinityCord for help is one major step that you shall make. We help you understand your own body and use stem cells to improve your immune system and prevent it from fighting itself. With us, you have the best chance of improving your life and setting yourself free from autoimmune disorders. Get in touch and let’s discuss it.
Choi. W. E. (2009). Adult Stem Cell Therapy for Autoimmune Disease. International Journal of Stem Cells. Retrieved April 10, 2020.
Laar. V. M. J. & Tyndall. A. (2006). Adult stem cells in the treatment of autoimmune diseases. British Society for Rheumatology. Retrieved April 10, 2020.
Muzes. G. et al. (2019). Issues and opportunities of stem cell therapy in autoimmune diseases. Retrieved April 10, 2020.
National Institutes of Health. (2016). Stem Cell Information. Autoimmune Diseases and the Promise of Stem Cell-Based. Retrieved April 10, 2020.
Ra. J. C. (2011). Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue-derived mesenchymal stem cells. BMC. Journal of Translational Medicine. Retrieved April 10, 2020.
Stem Cell Institute. (2017). Stem Cell Therapy for Autoimmune Diseases. Retrieved April 10, 2020.